Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SNY

Max Ratio

5.37

5Y Dividend Growth

17.00 %

Consecutive Years

2 years

5Y Average Payout Ratio

68.99 %
Forward Annual Dividend Yield 4.58 %
Consecutive Years 2
Forward Annual Dividend 2.21 USD
Consistent Years 2
Dividend CAGR 3Y 2.24 %
Continuous Dividends
Dividend CAGR 5Y 3.21 %
Payout Ratio TTM 75.31 %
Dividend CAGR 10Y 0.65 %
Ex Dividend Date 09.05.2025

Sanofi ADR

SNY
Current price
48.32 USD -0.33 USD (-0.68%)
Last closed 48.65 USD
ISIN US80105N1054
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 117 620 547 584 USD
Yield for 12 month -5.37 %
1Y
3Y
5Y
10Y
15Y
SNY
21.11.2021 - 28.11.2021

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab, as well as an strategic alliance with the Department of Health " Abu Dhabi for the development of global vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incor Address: 46, avenue de la Grande Armée, Paris, France, 75017

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

63.87 USD

P/E Ratio

16.66

Dividend Yield

4.58 %

Financials SNY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+51 498 342 927 USD

Last Year

+53 529 856 387 USD

Current Quarter

+12 333 275 190 USD

Last Quarter

+8 873 771 731 USD

Current Year

+36 142 799 000 USD

Last Year

+36 975 405 547 USD

Current Quarter

+8 973 777 545 USD

Last Quarter

+6 232 920 519 USD
EBITDA 12 147 999 744 USD
Operating Margin TTM 20.78 %
Price to Earnings 16.66
Return On Assets TTM 4.28 %
PEG Ratio 0.77
Return On Equity TTM 7.30 %
Wall Street Target Price 63.87 USD
Revenue TTM 45 165 998 080 USD
Book Value 61.83 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -4.60 %
Dividend Yield 4.58 %
Gross Profit TTM 32 050 999 296 USD
Earnings per share 2.90 USD
Diluted Eps TTM 2.90 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 67.20 %
Profit Margin 13.95 %

Stock Valuation SNY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 16.66
Forward PE 10.05
Enterprise Value Revenue 2.54
Price Sales TTM 2.60
Enterprise Value EBITDA 11.36
Price Book MRQ 1.35

Technical Indicators SNY

For 52 Weeks

43.86 USD 57.57 USD
50 Day MA 50.11 USD
Shares Short Prior Month 4 466 723
200 Day MA 51.93 USD
Short Ratio 2.04
Shares Short 4 392 782
Short Percent 0.21 %